Compare DIN & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIN | NGNE |
|---|---|---|
| Founded | 1958 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.8M | 327.8M |
| IPO Year | 1994 | 2014 |
| Metric | DIN | NGNE |
|---|---|---|
| Price | $30.48 | $27.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $29.00 | ★ $63.57 |
| AVG Volume (30 Days) | ★ 455.5K | 134.1K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $879,300,000.00 | N/A |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | $0.64 | N/A |
| P/E Ratio | $53.31 | ★ N/A |
| Revenue Growth | ★ 8.25 | N/A |
| 52 Week Low | $19.58 | $14.65 |
| 52 Week High | $39.68 | $37.27 |
| Indicator | DIN | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 57.60 | 50.39 |
| Support Level | $24.38 | $18.25 |
| Resistance Level | $31.83 | $29.05 |
| Average True Range (ATR) | 1.87 | 2.29 |
| MACD | 0.18 | -0.64 |
| Stochastic Oscillator | 71.66 | 20.69 |
Dine Brands Global Inc owns and franchises thousands of restaurants under the International House of Pancakes (IHOP), Applebee's Neighborhood Grill + Bar (Applebee's), and the Fuzzy's Taco Shop (Fuzzy's) names. The company conducts its business through three reportable segments: Franchise, Company-owned restaurants, and Rental. The majority of its revenue is generated from the Franchise segment, which consists of IHOP, Applebee's, and Fuzzy's franchise operations and generates revenue mainly from royalties and advertising fees from several IHOP, Applebee's, and Fuzzy's franchised restaurants, in addition to revenues from the sale of proprietary IHOP and Fuzzy's products to its franchisees. Geographically, the majority of the company's revenues is generated from its domestic market.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.